💨 Abstract

China's healthcare regulator has defended the efficacy of off-patent medicines used in public hospitals, stating that an investigation found concerns about their quality to be unsubstantiated. The regulator, National Healthcare Security Administration (NHSA), performed evaluations to ensure the consistency of generic drugs with original research drugs and closely supervised them post-approval.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖